Guillermo Gervasini1, Guadalupe García-Pino2, Esther Vergara3, Sonia Mota-Zamorano4, Montserrat García-Cerrada3, Enrique Luna2. 1. Department of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Av. Elvas s/n 06071, Badajoz, Spain. ggervasi@unex.es. 2. Service of Nephrology, Infanta Cristina University Hospital, Badajoz, Spain. 3. Service of Clinical Analyses, Don Benito-Villanueva Hospital, Villanueva de la Serena, Spain. 4. Department of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Av. Elvas s/n 06071, Badajoz, Spain.
Abstract
PURPOSE: We aimed to determine whether polymorphisms in CYP3A genes may affect the risk of acute rejection episodes (ARE) in renal transplant recipients treated with calcineurin inhibitors (CNIs). METHODS: One hundred and thirty seven patients and their respective donors were screened, by RT-PCR techniques, for three polymorphisms previously related with CNI pharmacokinetics and pharmacodynamics (CYP3A4*1B, CYP3A4*22 and CYP3A5*3). Genotypes of donors and recipients were associated by logistic regression models with ARE risk and exposure to CNIs. Clinical and pharmacokinetic parameters were recorded at four time-points after transplant (1 week and 1, 5 and 12 months). RESULTS: Nineteen patients (13.86%) experienced ARE. Patients who received a kidney from a donor carrying the CYP3A4*1B or CYP3A5*1 variant experienced ARE more frequently than those whose donor carried wild-type genotypes [OR = 6.29 (1.62-24.39), p = 0.008 and OR = 3.42 (1.06-11.01), p = 0.039, respectively]. The combined analysis of the CYP3A4*1B/3A5*1 alleles also revealed an increased risk in patients whose donors carried both variants [OR = 6.24 (1.60-24.33), p = 0.007]. The CYP3A genotype of the recipient did not affect ARE risk, although it did determine the degree of exposure to CNI throughout the first year after transplant. Patients with one or two variant alleles displayed lower concentration-to-dose ratios (CDRs) than non-carriers, with differences increasing with time after transplant (p values = 0.039, 0.004, 6.0 e-04 and 2.7 e-07 in the four time-points). CONCLUSIONS: Our preliminary findings suggest that the determination of the CYP3A genotype of the donor, but not that of the recipient, may be useful to predict the incidence of acute rejection in renal transplantation.
PURPOSE: We aimed to determine whether polymorphisms in CYP3A genes may affect the risk of acute rejection episodes (ARE) in renal transplant recipients treated with calcineurin inhibitors (CNIs). METHODS: One hundred and thirty seven patients and their respective donors were screened, by RT-PCR techniques, for three polymorphisms previously related with CNI pharmacokinetics and pharmacodynamics (CYP3A4*1B, CYP3A4*22 and CYP3A5*3). Genotypes of donors and recipients were associated by logistic regression models with ARE risk and exposure to CNIs. Clinical and pharmacokinetic parameters were recorded at four time-points after transplant (1 week and 1, 5 and 12 months). RESULTS: Nineteen patients (13.86%) experienced ARE. Patients who received a kidney from a donor carrying the CYP3A4*1B or CYP3A5*1 variant experienced ARE more frequently than those whose donor carried wild-type genotypes [OR = 6.29 (1.62-24.39), p = 0.008 and OR = 3.42 (1.06-11.01), p = 0.039, respectively]. The combined analysis of the CYP3A4*1B/3A5*1 alleles also revealed an increased risk in patients whose donors carried both variants [OR = 6.24 (1.60-24.33), p = 0.007]. The CYP3A genotype of the recipient did not affect ARE risk, although it did determine the degree of exposure to CNI throughout the first year after transplant. Patients with one or two variant alleles displayed lower concentration-to-dose ratios (CDRs) than non-carriers, with differences increasing with time after transplant (p values = 0.039, 0.004, 6.0 e-04 and 2.7 e-07 in the four time-points). CONCLUSIONS: Our preliminary findings suggest that the determination of the CYP3A genotype of the donor, but not that of the recipient, may be useful to predict the incidence of acute rejection in renal transplantation.
Entities:
Keywords:
Acute rejection; CYP3A4; CYP3A5; Renal transplant; Single nucleotide polymorphism
Authors: Niels Vincent Rekers; Tanja M Flaig; Marko J K Mallat; Marijke J Spruyt-Gerritse; Malu Zandbergen; Jacqueline D H Anholts; Ingeborg M Bajema; Marian C Clahsen-van Groningen; Jianxin Yang; Johan W de Fijter; Frans H J Claas; Susanne Brakemeier; Nils Lachmann; Reinhold Kreutz; Emile de Heer; Klemens Budde; Juliane Bolbrinker; Michael Eikmans Journal: Transplantation Date: 2017-09 Impact factor: 4.939
Authors: E Thervet; M A Loriot; S Barbier; M Buchler; M Ficheux; G Choukroun; O Toupance; G Touchard; C Alberti; P Le Pogamp; B Moulin; Y Le Meur; A E Heng; J F Subra; P Beaune; C Legendre Journal: Clin Pharmacol Ther Date: 2010-04-14 Impact factor: 6.875
Authors: Eric Thervet; Dany Anglicheau; Barry King; Marie-Hélène Schlageter; Bruno Cassinat; Philippe Beaune; Christophe Legendre; Ann K Daly Journal: Transplantation Date: 2003-10-27 Impact factor: 4.939
Authors: Dennis A Hesselink; Rachida Bouamar; Laure Elens; Ron H N van Schaik; Teun van Gelder Journal: Clin Pharmacokinet Date: 2014-02 Impact factor: 6.447
Authors: Karola Warzyszyńska; Michał Zawistowski; Edyta Karpeta; Agnieszka Jałbrzykowska; Maciej Kosieradzki Journal: Ann Transplant Date: 2022-07-26 Impact factor: 1.479
Authors: Miriam Saiz-Rodríguez; Susana Almenara; Marcos Navares-Gómez; Dolores Ochoa; Manuel Román; Pablo Zubiaur; Dora Koller; María Santos; Gina Mejía; Alberto M Borobia; Cristina Rodríguez-Antona; Francisco Abad-Santos Journal: Biomedicines Date: 2020-04-22